EZH2 and in situ carcinoma: Having demonstrated ARID1A protein loss in a subgroup of high-grade urothelial bladder tumors including CIS cases, we subsequently aimed to analyze a potential dependency of ARID1A-deficient urothelial cells on EZH2 for the first time.